{
    "title": "113_hr5790",
    "content": "The Act titled \"Health Prizes Rewarding Innovation, Savings, and Effectiveness Act of 2014\" introduces prize competitions for improving health outcomes and reducing federal expenditures under the Public Health Service Act. The Health Prizes Rewarding Innovation, Savings, and Effectiveness Act of 2014 aims to improve health outcomes and reduce Federal expenditures on health programs through prize competitions. The Director of NIH will identify 3 to 5 human diseases or health conditions in consultation with relevant experts. The Health Prizes Rewarding Innovation, Savings, and Effectiveness Act of 2014 requires the identification of 3 to 5 human diseases or health conditions with significant prevention and treatment spending by the Federal Government, but low research investment compared to other diseases. The Health Prizes Act of 2014 highlights the disparity in research investment for certain diseases compared to others with similar prevention and treatment spending by the Federal Government. It emphasizes the need for prize competitions to address this issue. The Health Prizes Act of 2014 emphasizes the need for prize competitions to address the disparity in research investment for diseases. The Director of NIH is required to design prize competitions to cooperate with competitors to achieve innovations for specific diseases or conditions. The Health Prizes Act of 2014 mandates prize competitions to drive innovations for diseases or conditions identified, awarding prizes to promising competitors. The Health Prizes Act of 2014 mandates prize competitions to drive innovations for diseases or conditions, awarding prizes to the most promising competitors with the best solutions. The design of these competitions must be realistic and unbiased. The Health Prizes Act of 2014 mandates prize competitions for disease innovations, ensuring realistic and unbiased design. Competitors can participate regardless of location or citizenship. The Health Prizes Act of 2014 mandates prize competitions for disease innovations, ensuring inclusivity regardless of location or citizenship. Competitors must address areas of unmet need and submit a report on the competition design. The Director of NIH consults with various experts in the process. The Health Prizes Act of 2014 mandates prize competitions for disease innovations, ensuring inclusivity regardless of location or citizenship. The Director of NIH consults with various experts, federal agencies, and conducts simulations as part of the process. The Director of NIH will award contracts for a simulation of prize competitions under the Health Prizes Act of 2014, based on designs developed in consultation with experts and agency heads. The Director of NIH will award contracts for a simulation of prize competitions under the Health Prizes Act of 2014, based on designs developed in consultation with experts and agency heads. Within 4 months of awarding the contracts, a report on the simulation and assessment results must be submitted to Congress. Adjustments to the design must be made within 21 months of the enactment of the Act. The Director of NIH will make adjustments to the design of prize competitions under the Health Prizes Act of 2014 based on simulation results and submit a report to Congress within 21 months of the Act's enactment. The Director of NIH will adjust prize competition designs and submit a report to Congress. Private entities will implement competitions based on these designs, requiring demonstration of innovation effectiveness within a 5-year period. The prize competitions, as adjusted under subsection (d), will require competitors to demonstrate innovation effectiveness over a period of not more than 5 years. The Secretary and the Commissioner of Food and Drugs may provide guidance and access to testing facilities to qualified competitors. The Director will conduct a total of not more than 5 prize competitions. The Director of NIH will conduct a total of not more than 5 prize competitions, with not more than 2 competitions per disease or condition. The Director will also track and report on the medical efficacy of innovations funded through the prize competitions. The Director of NIH will collect information on the medical efficacy and impact on Federal expenditures of innovations funded through prize competitions. Reports will be submitted to Congress annually for five years after the conclusion of the competitions. The Federal Government must report annually to Congress on information collected from prize competitions. The government cannot acquire intellectual property without participant consent, but can negotiate licenses for its use. Authorization of appropriations is required. The Federal Government may negotiate licenses for intellectual property developed in prize competitions, with an authorization of $50,000,000 for implementation. Under subsection (e), private entities receiving assistance for prize competitions must allocate at least 70% of the assistance as prizes for competitors, with a maximum of 30% for administration. Recipients of prizes from these competitions are excluded from including them in their gross income. Under subsection (e), private entities must allocate 70% of assistance as prizes for competitors in prize competitions. Recipients of these prizes are excluded from including them in their gross income. The amendment excludes certain prizes received by taxpayers from their gross income under section 409K of the Public Health Service Act. Effective for taxable years ending after the enactment of the Act."
}